Hong Kong, May 5, 2023 - In a landmark development for the pharmaceutical industry, Kingdom Investment Corporation Limited (KICL) and Elevatus Health Holding have joined forces through a strategic Joint Venture (JV) agreement. The signing ceremony, which took place in Hong Kong, marked the birth of a pioneering company registered in the USA, poised to revolutionize drug manufacturing and delivery on a global scale.
Under the visionary leadership of Mr. Hassan Omer Arteh, CEO of KICL, and Ms. Margaret Richardson, CEO of Elevatus Health Holding, Inc., this collaboration signals a significant leap forward in the pursuit of cutting-edge advancements in the healthcare sector.
The newly formed entity, aptly named Kingdom Elevatus, will spearhead transformative breakthroughs in the field of pharmaceuticals, with a strong emphasis on liposome and nano-particle drug delivery platforms. This strategic alliance aims to address critical shortages of generic pharmaceuticals and offer affordable medicines to people in need.
In the short term, Kingdom Elevatus will concentrate on overcoming the scarcity of vital generic drugs, particularly in the liposome and sterile-fill product categories. By leveraging their combined expertise, the joint venture seeks to overcome the high barriers to entry associated with these areas, ultimately providing patients with access to high-quality, cost-effective medications.
Looking ahead, Kingdom Elevatus has set its sights on becoming a global leader in liposome technology, with a specific focus on inflammation and oncology. Their medium-to-long-term goals involve investing in state-of-the-art manufacturing infrastructure and cultivating specialized knowledge to develop innovative drug delivery platforms. By establishing a direct-to-consumer network, Kingdom Elevatus aims to ensure efficient distribution of their pharmaceutical products.
Moreover, KICL and Elevatus Health Holding are committed to exploring the vast potential of biotechnology in the development market. Their shared vision centers around harnessing the power of biotechnology to develop affordable medicines, making healthcare more accessible to people worldwide.
The signing of the JV agreement between KICL and Elevatus Health Holding represents a momentous occasion that will reshape the pharmaceutical landscape. Through their collaboration, Kingdom Elevatus is poised to lead the way in revolutionizing drug delivery platforms, overcoming critical shortages, and making affordable medicines a reality for millions of individuals across the globe.
As Kingdom Elevatus embarks on this transformative journey, the world watches with anticipation as the fusion of cutting-edge technology, strategic expertise, and unwavering dedication promises to unlock a new era of healthcare innovation.
Comments